These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22280532)

  • 1. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
    Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
    Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
    Raza A; Lisak L; Billmeier J; Pervaiz H; Mumtaz M; Gohar S; Wahid K; Galili N
    Leuk Lymphoma; 2006 Mar; 47(3):433-40. PubMed ID: 16396766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
    J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
    Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
    Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
    Moon JH; Lee SJ; Lee YJ; Kang BW; Chae YS; Kim JG; Suh JS; Sohn SK
    Ann Hematol; 2012 Mar; 91(3):367-73. PubMed ID: 21947085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
    Zeidan AM; Borate U; Pollyea DA; Brunner AM; Roncolato F; Garcia JS; Filshie R; Odenike O; Watson AM; Krishnadasan R; Bajel A; Naqvi K; Zha J; Cheng WH; Zhou Y; Hoffman D; Harb JG; Potluri J; Garcia-Manero G
    Am J Hematol; 2023 Feb; 98(2):272-281. PubMed ID: 36309981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
    Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
    Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.